Oxford, UK, 03 April 2023
Nucleome Therapeutics appoints Jonny Wray, Ph.D. as Senior Vice President of Data Science and Informatics
Oxford, UK, 03 April 2023 – Nucleome Therapeutics Limited, (‘Nucleome’ or ‘the Company’), a biotechnology company decoding the dark matter of the human genome to discover first-in-class precision medicines, today announces the appointment of Dr Jonny Wray as Senior Vice President of Data Science and Informatics, effective immediately.
Jonny is a highly skilled informatician with cross-domain expertise in drug discovery informatics, data science and computational biology. He brings more than 30 years of experience in devising and building computational, data-driven solutions to complex biological problems.
Prior to joining Nucleome Therapeutics, Jonny was the Chief Technology Officer of e-therapeutics plc where he was responsible for conceptualizing and building their computational drug discovery platform. Prior to this he held leadership roles in bioinformatics and software engineering at Five Prime Therapeutics and BD Clontech, both in the San Francisco Bay Area.
Dr Danuta Jeziorska, Chief Executive Officer and Co-founder of Nucleome Therapeutics, said: “Jonny’s experience will be invaluable as we advance our pioneering technology to decode the dark matter of the human genome. We look forward to working with him to further establish our robust 3D genomics platform to revolutionise drug target discovery.”
Dr Jonny Wray, Senior Vice President of Data Science and Informatics at Nucleome Therapeutics, added: “Nucleome’s platform has the potential to drive a paradigm shift in drug discovery. I am delighted to be joining the team at such a crucial point in the Company’s growth. I look forward to working with the computational scientists and applying my experience in building robust complex computational systems for drug discovery.”
Jonny holds a PhD from the University of Newcastle and has conducted post-doctoral work as a Fellow in Theoretical Neuroscience at The Neurosciences Institute (New York and San Diego) where his research was aimed at understanding how brain function arises from network structure.
For more information, please contact:
About Nucleome Therapeutics
Nucleome Therapeutics is decoding the dark matter of the human genome to uncover novel ways to treat disease. The dark genome holds more than 90% of disease-linked genetic variants whose value remains untapped, representing a significant opportunity for drug discovery and development. The Company has the unique ability to link these variants to gene function and precisely map disease pathways. Nucleome’s cell type-specific platform creates high resolution 3D genome structure maps and enables variant functional validation at scale in primary cell types, enabling the discovery and development of novel, better and safer drugs. The initial focus of the company is on lymphocytes and related autoimmune disease. Nucleome’s ambition is to build a robust pipeline of drug assets, with corresponding biomarkers. Nucleome Therapeutics was founded by leading experts in gene regulation from the University of Oxford. For more information, please visit www.nucleome.com.